99% β-Nicotinamide mononucleotide (NMN) CAS 1094-61-7

ʻO ka β-nicotinamide mononucleotide, a i ʻole "NMN" no ka pōkole, he nucleotide hana kūlohelohe maoli.ʻElua mau ʻano like ʻole o ka NMN, α a me β;ʻO ka isomer β ka ʻano hana o NMN me ke kaumaha molekala o 334.221 g/mol.No ka mea aia ka nicotinamide i ka huaora B3, aia ka NMN i ka ʻāpana o nā huaʻai B derivatives.Hoʻopili nui ia i nā hopena biochemical i loko o ke kino o ke kanaka a pili pono i ka pale a me ka metabolism.
ʻO nā mea i loaʻa i loko o ke kino o ke kanaka ka waiwai nui i kekahi mau huaʻai a me nā mea kanu.I loko o ke kino o ke kanaka, ʻo NMN ka precursor pololei loa o NAD +, a ʻike ʻia kāna hana e NAD +.ʻIke ʻia ʻo NAD+ he coenzyme I, ka inoa piha o ka nicotinamide adenine dinucleotide, aia i loko o kēlā me kēia cell a komo i nā tausani o nā hopena.Ma nā ʻano like ʻole o ka hoʻololi ʻana i ka metabolic cellular, ʻo nā molekala nicotinamide adenine dinucleotide (NAD) he kuleana koʻikoʻi a he kākoʻo koʻikoʻi ia no ka hiki ʻana o ke kelepona.
ʻO ka emi ʻana o ka NAD i ka wā ʻelemakule i manaʻo ʻia he kumu nui o ka maʻi a me ke kīnā, e like me ka nalo ʻana o ka lohe a me ka ʻike, cognitive a me ka motor dysfunction, immunodeficiency, arthritis ma muli o ka dysregulated autoimmune inflammatory pane, metabolic disorders, a me ka maʻi cardiovascular.No laila, hoʻonui ka NMN supplementation i ka ʻike NAD + i loko o ke kino, no laila ke kali nei, hoʻomaikaʻi, a pale aku i nā ʻano phenotypes e pili ana i ka ʻelemakule, a i ʻole nā ​​​​maʻi metabolic i hoʻoulu ʻia i ka makahiki, nā maʻi senile, etc.